Furthermore, targeting secondary glutamine transporters (e.g., SLC38A2, SLC6A14) genetically or pharmacologically (e.g., α-methyltryptophan) significantly suppresses amino acid homeostasis and tumor growth in pancreatic cancer [60,61]. The gene discussed is SLC38A2; the disease is familial pancreatic carcinoma.